Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Key Takeaways

• Q4 ZUNVEYL revenue $2.5M, total 2025 $10.2M.
• Prescriber base grew 50% QoQ, bottles up 62%.
• SG&A expenses jumped to $29.1M, widening operating loss.
• Cash balance $66M provides roughly two‑year runway.
• Second national PBM contract covers two of four major payers.

Summary

Alpha Cognition reported fourth‑quarter 2025 revenue of $2.5 million from its Alzheimer’s drug ZUNVEYL, bringing full‑year revenue to about $10.2 million. The company added a second national PBM contract, expanding coverage to two of the four major long‑term‑care payers, and saw prescriber numbers rise 50% quarter‑over‑quarter. Operating loss widened to $22.7 million as SG&A expenses surged to $29.1 million, while cash on hand grew to $66 million, enough for roughly two years of operations. Management highlighted upcoming clinical data presentations and a sublingual formulation slated for 2026.

Pulse Analysis

ZUNVEYL’s entry into the Alzheimer’s market marks a rare breakthrough, as the last oral therapy received approval over a decade ago. Its patented acetylcholinesterase inhibition with a favorable gastrointestinal profile positions it against established cholinesterase inhibitors, while the sublingual formulation in development could address dysphagia‑related adherence challenges. Analysts are watching adoption rates in long‑term‑care facilities, where repeat ordering signals a shift from trial use to routine therapy, potentially reshaping payer formularies.

Financially, Alpha Cognition’s 2025 results illustrate a classic growth‑stage trade‑off. Revenue climbed to $10.2 million, yet SG&A surged to $29.1 million, driving an operating loss of $22.7 million. The company trimmed R&D spend, but the net cash position rose to $66 million, extending the runway to about two years at current burn. Investors will weigh whether the expanding commercial footprint and PBM contracts can translate into margin improvement before the anticipated 2027 profitability target.

Looking ahead, Alpha Cognition’s pipeline and real‑world evidence initiatives could reinforce ZUNVEYL’s market position. The BEACON effectiveness study and upcoming CONVERGE and RESOLVE trials aim to validate cognitive and behavioral benefits, while two ex‑US approvals via a partner in Asia could diversify revenue streams. Coupled with the sublingual formulation for patients with swallowing difficulties, the company is building a multi‑pronged strategy to deepen prescriber engagement and capture a larger share of the growing Alzheimer’s therapeutics market.